



IFW

TRANSMITTAL LETTER

Docket No. V0002/7004

Applicant: Mats J. Olsson
Serial No: 10/579,566
Conf. No: 5509
Filed: May 12, 2006
For: MELANOCYTES IN THERAPY OF NEURODEGENERATIVE DISEASES
Examiner: TBA
Art. Unit: TBA

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Enclosures

- | | |
|--|---|
| <input type="checkbox"/> Affidavit under 37 C.F.R. 1.131 | <input type="checkbox"/> Request for Corrected Filing Receipt |
| <input type="checkbox"/> Assignment Papers | <input type="checkbox"/> Copy of Original Filing Receipt |
| <input type="checkbox"/> Change of Correspondence Address | <input type="checkbox"/> Request for Continued Examination |
| <input type="checkbox"/> Declaration/Power of Attorney | <input type="checkbox"/> Request for Reconsideration |
| <input type="checkbox"/> Extension of Time Request | <input type="checkbox"/> Request for Refund |
| <input type="checkbox"/> Fee Transmittal Form | <input type="checkbox"/> Response to Missing Parts |
| <input checked="" type="checkbox"/> Information Disclosure Statement | <input checked="" type="checkbox"/> Return Receipt Postcard |
| <input type="checkbox"/> Power of Attorney Form | <input type="checkbox"/> Terminal Disclaimer |
| <input type="checkbox"/> Request for Certified Copies | <input type="checkbox"/> Other: |

Authorization to Charge Additional Fees

- ☒ The Commissioner is hereby authorized to charge any additional fees under 37 C.F.R. §1.16 and §1.17 required by the attached papers and during the entire pendency of this application to Account No. 02-3038.

Date: 5 Sept 06

Therese A. Hendricks, Esq., Reg. No. 30,389
Rissman Jobse Hendricks & Oliverio, LLP
Customer Number 021127
Tel: (617) 367-4600 Fax: (617) 367-4656

INFORMATION DISCLOSURE TRANSMITTAL

Docket No. V0002/7004

Applicant: Mats J. Olsson
Serial No: 10/579,566
Filed: May 12, 2006
For: MELANOCYTES IN THERAPY OF NEURODEGENERATIVE DISEASES
Examiner: TBA
Art Unit: TBA

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on 9/5/2006.


Judith M. Schultz

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

In keeping with the duty of candor and good faith owed to the Patent and Trademark Office, Applicant wishes to bring information to the attention of the Examiner. The filing of this statement shall not be construed as a representation that a search has been made or as an admission that this information is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

Enclosures

- ☒ A form PTO-1449 listing this information is attached
☒ Copies of documents cited, other than U.S. patents and published U.S. patent applications, are enclosed.
☐ Copies of the cited documents are not enclosed because

Fees

- ☒ This statement is filed before the later of: (1) three months of (i) the filing of a national application or (ii) the entry date for the national stage of an international application; (2) the mailing date of a first office action on the merits; or (3) the mailing date of a first office action on the merits following the filing of a Request for Continued Examination. No fee is due.
- ☐ This statement is filed before the mailing date of a final office action, a notice of allowance or an action that otherwise closes prosecution, and
- ☐ The submission fee of \$180.00 under 37 CFR §1.17(p) is enclosed, or
- ☐ The following certification is made:
- ☐ each item of information contained in this statement was cited in a communication from a foreign patent office in a counterpart foreign

application not more than three months prior to the filing of this statement,
or

- ☐ no item of information contained in this statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing the statement after making reasonable inquiry, no item of information contained in this statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

- ☐ This statement is filed on or before payment of the issue fee, the submission fee of \$180.00 under 37 CFR §1.17(p) is enclosed, and

- ☐ each item of information contained in this statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement, or
- ☐ no item of information contained in this statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing the statement after making reasonable inquiry, no item of information contained in this statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

Payment

- ☐ A check in the amount of the submission fee is enclosed.
- ☐ Charge Account No. 02-3038 in the amount of the submission fee. A duplicate of this transmittal sheet is attached.

Authorization to Charge Additional Fees


- ☒ The Commissioner is hereby authorized to charge any additional fees under 37 C.F.R. §1.16 and §1.17 required by the attached paper and during the entire pendency of this application to Account No. 02-3038.

Respectfully submitted,



Date: 5 Sept 2006

Therese A. Hendricks, Esq., Reg. No. 30,389
RISSMAN JOBSE HENDRICKS & OLIVERIO, LLP
Customer Number 021127
Tel: (617) 367-4600 Fax: (617) 367-4656



INFORMATION DISCLOSURE STATEMENT BY APPLICANT Sheet 1 of 2

Docket No. V0002/7004

Applicant: Mats J. Olsson
 Serial No: 10/579,566
 Filed: May 12, 2006
 For: MELANOCYTES IN THERAPY OF NEURODEGENERATIVE DISEASES
 Examiner: TBA
 Art Unit: TBA

OTHER PRIOR ART – NON PATENT LITERATURE AND DOCUMENTS

Exam Inits	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the articles (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	1	International Search Report and Written Opinion from priority application PCT/SE2004/001663	<input type="checkbox"/>
	2	ABDEL-NASER, M.B., Mitogen requirements of normal epidermal human melanocytes in a serum and tumor promoter free medium, European Journal of Dermatology, volume 13, no. 1, 2003, 29-33.	<input type="checkbox"/>
	3	DONATIEN et al., Growth and differentiation of normal human melanocytes in a TPA-free, cholera toxin-free, low-serum medium and influence of keratinocytes, Arch Dermatol Res, volume 285, 1993, 385-392.	<input type="checkbox"/>
	4	OLSSON et al., Long-term follow-up of leucoderma patients treated with transplants of autologous cultured melanocytes, ultrathin epidermal sheets and basal cell layer suspension, British Journal of Dermatology, volume 147, 2002, 893-904.	<input type="checkbox"/>
	5	AHMED et al., Differential Trypsinization – Selective Adhesion Technique for Cultivation of Normal Adult Human Melanocytes in Phorbol Acetate-Free and Cholera Toxin-Free Medium, Journal of Investigative Dermatology, volume 106, no. 4, 1996.	<input type="checkbox"/>
	6	HARA et al., Innervation of Melanocytes in Human Skin, J. Exp. Med., Vol. 184, pp. 1384-1395, Oct. 1996.	
	7	LIM, H. et al., Minireview: A Novel Pathway of Prostacyclin Signaling – Hanging Out with Nuclear Receptors, Endocrinology 143, pp. 3207-3210, Sept. 2002.	
	8	EISENHOFER, G. et al., Tyrosinase: a developmentally specific major determinant of peripheral dopamine, The FASEB Journal, pp. 1248-1255, July 2003.	
	9	LIM, H. et al., PPARs Functions as a Prostacyclin Receptor in Blastocyst Implantation, TEM Vol. 11, No. 4, 2000.	
	10	ALEXI, T. et al., Neuroprotective strategies for basal ganglia degeneration: Parkinson's and Huntington's diseases, Progress in Neurobiology, No. 60, pp. 409-470, 2000.	

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT Sheet 2 of 2**

Docket No. V0002/7004

Applicant: Mats J. Olsson
 Serial No: 10/579,566
 Filed: May 12, 2006
 For: MELANOCYTES IN THERAPY OF NEURODEGENERATIVE DISEASES
 Examiner: TBA
 Art Unit: TBA

11	MARLES, L.K. et al., Tyrosine hydroxylase isoenzyme I is present in human melanosomes: a possible novel function in pigmentation, Pigment Cell Research, No. 12, pp. 61-70, Sept. 2002.
12	MARS, U., Melanogenesis as the Basis for Melanoma Targeting, Acta Universitatis Upsaliensis, 1998.
13	OLSSON, M.J. et al., Vitiligo: Repigmentation with Cultured Melanocytes after Cryostorage, Acta Derm Venereol (Stockh) 74, pp. 226,228, 1994.
14	LERNER, M.R., Tools for investigating functional interactions between ligands and G-protein-coupled receptors, TINS No. 17, No. 4, 1994.
15	AL'ABADIE, M.S.K. et al., Neuropeptide and neuronal marker studies in vitiligo, British Journal of Dermatology 131, pp. 106-165, Jan. 1995.
16	HRISTAKIEWA, E. et al., Markers for Vitiligo Related Neuropeptides in Human Skin Nerve Fibers, Acta med. Croatica, No. 563, pp. 53-57, 1999.
17	JIMBOW, K., Review: Current Update and Trends in Melanin Pigmentation and Melanin Biology, Keio J. Med., 44 (1), pp. 9-18, 1995.

Examiner
Signature

Date
Considered